Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Exelixis has signed a cooperative research and development agreement (CRADA) with the National Cancer Institute's (NCI) Cancer Therapy Evaluation Program (CTEP) to further assess company's cabozantinib in a variety of solid tumors.
Subscribe to our email newsletter
Cabozantinib is a potent, dual inhibitor of MET and VEGFR2.
Exelixis and the NCI will carry out a series of clinical trials to assess the safety and efficacy of cabozantinib in several cancers based upon encouraging anti-tumor activity observed in earlier studies, as per the agreement.
The trials will be designed to address a number of scientific questions such as how the efficacy of cabozantinib compares with other VEGFR2 inhibitors, the ability of cabozantinib to overcome resistance of tumors to VEGFR2 or EGFR inhibition, and the mechanism of activity of cabozantinib in tumors metastatic to bone.
Based upon the data obatined from the CTEP-sponsored studies and other Exelixis-sponsored trials, the NCI and Exelixis will discuss about additional trials.
The NCI will support non-clinical studies that focus on identifying assays for monitoring the biologic activity of cabozantinib, as well as combination studies of the compound with other targeted agents.
Exelixis president and CEO Michael Morrissey said their CRADA with the NCI’s Division of Cancer Treatment and Diagnosis reinforces their commitment to maximize the broad clinical potential of cabozantinib in a wide variety of tumor indications while focusing their own internal efforts on prostate and thyroid cancer.
"We hope the CTEP collaboration will provide additional clinical data that will highlight cabozantinib’s differentiated clinical profile in multiple different cancer indications," Morrissey said.